Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis

INTRODUCTION: Biosimilar infliximab has the potential for appreciable cost savings compared to its reference biologic, but dose escalation is common and increases costs. We compared frequency of dose escalation and associated Medicare-approved amount so as to determine the break-even point at which...

Descripción completa

Detalles Bibliográficos
Autores principales: Curtis, Jeffrey R., Xie, Fenglong, Kay, Jonathan, Kallich, Joel D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6909454/
https://www.ncbi.nlm.nih.gov/pubmed/31831064
http://dx.doi.org/10.1186/s13075-019-2022-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6909454/
https://www.ncbi.nlm.nih.gov/pubmed/31831064
http://dx.doi.org/10.1186/s13075-019-2022-8

Ejemplares similares